Calidi Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.11M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | – | $-2.94 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | – | $-0.43 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | During market hours | – | $0.57 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | – | $-2.21 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | During market hours | – | $-1.99 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | – | $-0.18 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | – | $-0.27 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | $-0.65 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 18, 2024 | Before market open | – | – | – |
Press releases
Announcements Calidi Biotherapeutics filed with the SEC
Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Listing notice · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces $1.2 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Announces Proposed Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’
Material agreement · Unregistered share sale · Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
Results of operations · Other events · EX-99.1 to Form 8-K
Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CALIDI BIOTHERAPEUTICS PRESENTS NEW DATA ON ITS THERAPEUTIC LEAD, CLD-401, AT THE 2025 SITC ANNUAL MEETING AND HOLDS ITS FIRST INVESTOR DAY AT SITC
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment
Material agreement · Other events · EX-99.2 to Form 8-K
Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Calidi Biotherapeutics Reports First Quarter 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
Material agreement · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Appointment of Guy Travis Clifton, MD
Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
Agreement terminated · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Calidi Biotherapeutics Announces Proposed Public
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Biotherapeutics Announces Proposed Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.3 to Form 8-K
Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K